ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mavacamten

Also written as “Mavacamten” and “MYK-461”.

Its studies are mostly in Cardiomyopathy, Hypertrophic · Anthrax, led by 2 companies.

Drug pageMYK-461: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 27, 202321 company-led studies, 4 open or runningNext primary completion: Dec 13, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only194 open or runningphase 4since Oct 27, 2023Dec 19, 2014Dec 13, 2027phase 4 · NCT07004972
LianBio20 open or runningphase 3since Dec 13, 2021Oct 28, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of LianBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2016Named mavacamtenINNProposed as its International Nonproprietary Name in WHO's List 116 · before, MYK-461
  2. Oct 28, 2021First study: phase 1 study in Cardiomyopathy, HypertrophicFirst studyNCT05135871 · 45 enrolled · China
  3. Dec 13, 2021Phase 3 study in Cardiomyopathy, HypertrophicNCT05174416 · 81 enrolled · China

TargetBeta

“Cardiac myosin inhibitor”ChEMBL 37, by rule

Other programs on the same 7 targets

ProgramCompanyFurthest phaseStudies
omecamtiv mecarbilruleCytokineticsphase 316
danicamtivruleBristol-Myers Squibbphase 37

Studies

All 2 LianBio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05174416Cardiomyopathy, Hypertrophic · China3CompletedMar 6, 202381
NCT05135871Cardiomyopathy, Hypertrophic · China1CompletedFeb 5, 202245

How it is read

Names in the registry

  • “Mavacamten”, 12 entries
  • “mavacamten”, 5 entries
  • “MYK-461”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.